高级搜索

MTHFR基因多态性与结肠癌患者术后FOLFOX4辅助化疗疗效的关系

仇宇, 周春花, 杨农, 李坤艳, 王静, 刘先领

仇宇, 周春花, 杨农, 李坤艳, 王静, 刘先领. MTHFR基因多态性与结肠癌患者术后FOLFOX4辅助化疗疗效的关系[J]. 肿瘤防治研究, 2013, 40(06): 595-598. DOI: 10.3971/j.issn.1000-8578.2013.06.022
引用本文: 仇宇, 周春花, 杨农, 李坤艳, 王静, 刘先领. MTHFR基因多态性与结肠癌患者术后FOLFOX4辅助化疗疗效的关系[J]. 肿瘤防治研究, 2013, 40(06): 595-598. DOI: 10.3971/j.issn.1000-8578.2013.06.022
QIU Yu, ZHOU Chunhua, YANG Nong, LI Kunyan, WANG Jing, LIU Xianling. Relationship between Polymorphism of MTHFR and Curative Effect of FOLFOX4 Adjuvant Chemotherapy in Postoperative Colon Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2013, 40(06): 595-598. DOI: 10.3971/j.issn.1000-8578.2013.06.022
Citation: QIU Yu, ZHOU Chunhua, YANG Nong, LI Kunyan, WANG Jing, LIU Xianling. Relationship between Polymorphism of MTHFR and Curative Effect of FOLFOX4 Adjuvant Chemotherapy in Postoperative Colon Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2013, 40(06): 595-598. DOI: 10.3971/j.issn.1000-8578.2013.06.022

MTHFR基因多态性与结肠癌患者术后FOLFOX4辅助化疗疗效的关系

详细信息
    作者简介:

    仇宇(1976-),男,硕士,主管药师,主要从事肿瘤药物治疗的相关基因多态性研究

    通讯作者:

    刘先领,E-mail:liuxianling3180@ yahoo.com.cn

  • 中图分类号: R735.3+5

Relationship between Polymorphism of MTHFR and Curative Effect of FOLFOX4 Adjuvant Chemotherapy in Postoperative Colon Cancer Patients

  • 摘要: 目的 研究亚甲基四氢叶酸还原酶基因(MTHFR)C677T多态性与结肠癌术后患者接受FOLFOX4辅助化疗疗效的关系。 方法 对行结肠癌根治术后接受FOLFOX4方案化疗6周期的76例患者,采用焦磷酸测序法检测MTHFR C677T 基因多态。 结果 76例Ⅱ、Ⅲ期结肠癌患者的MTHFR-C677T位点存在3种等位基因型,其基因频率分别为:C/C 47.4%(36/76),T/C40.8%(31/76),T/T11.8%(9/76)。C/C 基因型36例中复发11例,T/C基因型31例中复发13例,T/T基因型9例中复发2例,T/T基因型复发比率小于C/C+ T/C基因型(22.2% vs.35.8%),但差异无统计学意义(P=0.710)。 结论 MTHFR-C677T基因多态性与结肠癌FOLFOX4辅助化疗疗效无关。

     

    Abstract: Objective To study the relationship between polymorphism of methylenetetrahydrofolate reductase (MTHFR) and FOLFOX4 adjuvant chemotherapy in postoperative colon cancer patients. Methods A total of 76 postoperative colon cancer patients were enrolled and recived six cycles of FOLFOX4 adjuvant chemotherapy MTHFR C677T gene polymorphism was detected by pyrophosphoric acid sequencing method. Results The three allelotypes of the MTHFR-C677T in 76 patients were C/C 47.4%(36/76), T/C40.8%(31/76), T/T11.8%(9/76). The relapsed cases were 11 in C/C, 13 in T/C, 9 in T/T.The relapsed rate in T/T was similar to C/C and T/C (P=0.710). Conclusion There had no relationship between MTHFR C677T mutation and curative effect of FOLFOX4 adjuvant chemotherapy in postoperative colon cancer patients.

     

  • [1] Kremer JM.MethotrexatePharmacogenomics[J]Ann Rheum Dis,2006,65(9):1121-3.
    [2] Afzal S,Jensen SA,Vainer B,et al.MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer[J].Ann Oncol,2009,20(10):1660-6.
    [3] Thomas F, Motsinger-Reif AA, Hoskins JM,et al. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer[J].Br J Cancer,2011,22,105 (11):1654-62.
    [4] Giacomini KM,Brett CM,Altman RB,et al.The pharmacogenetics research network: from SNP discovery to clinical drug response[J].Clin Pharmacol Ther, 2007, 81(3):328-45.
    [5] Wan DS.Chinical oncology[J].Two edition.Beijing: Science and Technology Press,2005:348-9.[万德森. 临床肿瘤学[M]. 2版. 北京: 科技出版社,2005:348-9.]
    [6] Siegel R, Naishadham D, Jemal A.Cancer statistics[J]. CA Cancer J Clin,2012,62(1):10-29.
    [7] Lin YL, Liang JT. FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients[J]. Hepatogastroenterology,2012,59(114):400-4.
    [8] Sugihara K, Ohtsu A, Shimada Y,et al.Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies [J].Clin Colorectal Cancer,2012,11(2):127-37.
    [9] Jeon HJ, Woo JH, Lee HY, et al.Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer [J].J Korean Soc Coloproctol,2011,27(3):140-6.
    [10] Lu GC, Fang F, Li DC.Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer[J].Zhonghua Zhong Liu Za Zhi,2010,32(2):152-5. [卢国春,方 复,李德川.卡培他滨联合奥沙利铂与5-氟尿嘧啶亚叶酸钙联合奥沙利铂在Ⅲ期结直肠癌辅助化疗中的疗效和安全性 比较[J].中华肿瘤杂志,2010.32(2):152-5.]
    [11] Lombardi L,Gebbia V,Silvestris N,et al. Adjuvant therapy in colon cancer [J].Oncology,2009,77 Suppl 1:50-6.
    [12] Huang ZH,Hua D,Li LH,et al.The prognostic impact of MTHFR C677T polymorphism on gastric cancer patients treated with adjuvant chemotherapy[J].Lin Chuang Zhong Liu Xue Za Zhi,2008,14(4):243-47.[黄朝 晖,华东,李莉华,等.MTHFR C677T 基因多态对胃癌辅助化疗预后的影响[J].临床肿瘤学杂志,2008,14(4):243- 47.]
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-01-06
  • 修回日期:  2013-04-09
  • 刊出日期:  2013-06-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭